Objective: Our aim was to clearly evaluate the Prognostic Nutritional Index's ability to predict chemotherapy-induced toxicity in ovarian cancer patients undergoing platinum-based chemotherapy.Study Design: This retrospective cohort study of 158 patients with epithelial ovarian cancer treated with carboplatin-paclitaxel after surgery at a university hospital from 2010 to 2020 decisively investigates the Prognostic Nutritional Index (PNI) as a predictor of chemotherapy-related toxicities. PNI was calculated using pre-treatment serum albumin levels and lymphocyte counts. Results: The findings clearly demonstrate that patients with a PNI ≤34.10 experienced higher overall and severe hematologic toxicities compared to those with a higher PNI. Dose reductions and treatment delays were markedly more frequent in the low PNI group. Conclusion: This study establishes that PNI is a valuable tool for assessing patient risk, though further validation will enhance its clinical utility.
Erturun et al. (Thu,) studied this question.